---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-24-000003"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:26:01.488872+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Halozyme prelim FY2023 revenue $827-832M; GAAP EPS $2.18-2.21

## Summary
- Revenue estimated $827-832M; royalties $445-450M for FY2023.
- Net income $292-297M; EBITDA $435-440M; adjusted EBITDA $425-430M.
- GAAP diluted EPS $2.18-2.21; non-GAAP diluted EPS $2.77-2.80.
- Preliminary unaudited estimates subject to completion of year-end close.

## SEC filing metadata
- accession: 0001159036-24-000003
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/0001159036-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/halo-20240117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-24-000003
- JSON: https://secwatch.observer/filing/0001159036-24-000003.json
- Plain text: https://secwatch.observer/filing/0001159036-24-000003.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported Twelve Months Ended December 31, 2023 results: revenue $827 million to $832 million, net income $292 million to $297 million, EPS GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80.
  - Period: Twelve Months Ended December 31, 2023
  - Revenue: $827 million to $832 million
  - Net income: $292 million to $297 million
  - EPS: GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80
  - Result: preliminary results
  source text: this preliminary information. Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2023 The Company estimates 2023 Revenue will be in the range of $827 million to $832 million. The Company estimates 2023 royalties will be in the range of $445 million to $450 million. The Company estimates 2023 Net Income will be in the range of $292
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/0001159036-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.